Storm Therapeutics
California, USA and Cambridge, UK. 14 October 2021. STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform. Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today […]
Storm’s First-in-Class clinical candidate against an RNA Methyltransferase for use in Cancer was identifed with support from Evotec’s Drug Discovery Engine. Storm will progress the compound towards the clinic using indigo, Evotec’s integrated Ivestigational New Drug […]
Cambridge, UK. 22 October 2020. Seroba’s investee company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has announced that STC-15, its first-in-class drug candidate targeting […]
Dublin, Ireland. 9 September 2020. FutureNeuro has announced that it has entered into partnership with Seroba’s portfolio company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA […]
Cambridge, UK. 18 September 2019. STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies modulating RNA epigenetics, announced today that Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, will present first […]
Cambridge, UK. 20 May 2019. STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, has announced that it has raised an additional £14 million bringing its total Series A financing to […]
